KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Tax Provisions (2016 - 2025)

BeOne Medicines (ONC) has disclosed Tax Provisions for 10 consecutive years, with $22.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Tax Provisions fell 3.14% to $22.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $113.7 million, a 83.3% increase, with the full-year FY2024 number at $111.8 million, up 100.07% from a year prior.
  • Tax Provisions was $22.3 million for Q3 2025 at BeOne Medicines, up from $5.2 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $66.5 million in Q4 2024 to a low of -$29.1 million in Q4 2022.
  • A 5-year average of $11.5 million and a median of $13.0 million in 2022 define the central range for Tax Provisions.
  • Biggest YoY gain for Tax Provisions was 6127.83% in 2022; the steepest drop was 16414.77% in 2022.
  • BeOne Medicines' Tax Provisions stood at -$176000.0 in 2021, then crashed by 16414.77% to -$29.1 million in 2022, then skyrocketed by 157.73% to $16.8 million in 2023, then surged by 296.46% to $66.5 million in 2024, then crashed by 66.45% to $22.3 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Tax Provisions are $22.3 million (Q3 2025), $5.2 million (Q2 2025), and $19.6 million (Q1 2025).